GeneDx Holdings (WGS) Operating Expenses (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Operating Expenses data on file, last reported at $94.4 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $94.4 million, up 49.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $272.5 million (up 52.87% YoY), and the FY2025 annual result was $222.8 million, up 48.33% from the prior year.
• Operating Expenses advanced to $94.4 million in Q1 2026 per WGS's latest filing, from $71.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $98.5 million in Q2 2022 and troughed at $35.0 million in Q1 2024.
• A 5-year average of $58.0 million and a median of $58.3 million in 2023 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 296.8% in 2022 and fell as far as 56.17% in 2022.
• A 5-year view of Operating Expenses shows it stood at $67.6 million in 2022, then slumped by 34.68% to $44.1 million in 2023, then fell by 10.01% to $39.7 million in 2024, then jumped by 79.67% to $71.4 million in 2025, then soared by 32.26% to $94.4 million in 2026.
• Business Quant data shows WGS's Operating Expenses at $94.4 million in Q1 2026, $71.4 million in Q4 2025, and $64.3 million in Q3 2025.